Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

BACKGROUND: ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC201 previously established a recommended phase II...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Stein, Mark N., Malhotra, Jyoti, Tarapore, Rohinton S., Malhotra, Usha, Silk, Ann W., Chan, Nancy, Rodriguez, Lorna, Aisner, Joseph, Aiken, Robert D., Mayer, Tina, Haffty, Bruce G., Newman, Jenna H., Aspromonte, Salvatore M., Bommareddy, Praveen K., Estupinian, Ricardo, Chesson, Charles B., Sadimin, Evita T., Li, Shengguo, Medina, Daniel J., Saunders, Tracie, Frankel, Melissa, Kareddula, Aparna, Damare, Sherrie, Wesolowsky, Elayne, Gabel, Christian, El-Deiry, Wafik S., Prabhu, Varun V., Allen, Joshua E., Stogniew, Martin, Oster, Wolfgang, Bertino, Joseph R., Libutti, Steven K., Mehnert, Janice M., Zloza, Andrew
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6532211/
https://ncbi.nlm.nih.gov/pubmed/31118108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0599-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items